Alkermes ( (ALKS) ) has shared an announcement.
Alkermes plc recently showcased its orexin portfolio and development strategy, emphasizing the potential of its leading compound, ALKS 2680, to address sleep disorders such as narcolepsy and idiopathic hypersomnia. While highlighting the significance of the orexin 2 receptor pathway in regulating sleep, mood, and cognition, Alkermes stressed that these investigational compounds are still in the clinical trial phase and their safety and efficacy have not been fully established. The event also included discussions on the molecular design and pharmacokinetics necessary to replicate the natural sleep/wake cycle and cater to different patient needs.
For an in-depth examination of ALKS stock, go to TipRanks’ Stock Analysis page.
